Clinical Trial Update: A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating aticaprant 10 mg as adjunctive therapy for adults with major depressive disorder and moderate-to-severe anhedonia has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Aticaprant (Aticaprant)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Depressive Disorder, Major, Anhedonia | Phase 3 | Status: TERMINATED